Charles River Laboratories International Inc at Barclays Global Healthcare Conference Transcript
Thank you, and good morning. This is Jack Meehan with the Life Science Tools & Diagnostics team here at Barclays. And pleased to be continuing the Barclays virtual Global Healthcare Conference now with Charles River Chairman and CEO, Jim Foster; as well as Head of Investor Relations, Todd Spencer. I appreciate you guys joining us in the new format. And Jim, just like to turn it over to you for some introductory comments.
Sure. Thanks. Thanks, Jack. We reported a very strong '19. Sales up 8.5%. Operating margins 19%, up 20 bps. EPS $6.73, up 16%. We were really, really pleased with those results. The guidance for '20 is 7.75% to 8.75% revenue growth and EPS at $7.45 to $7.60.
The RMS segment was up 5 -- a little over 5%, driven principally by China and strength in our GEMS business and IS business. We opened a new facility in South San Francisco, which is an incubated
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
